22nd Century Group is to announce its full year results on 1st March, after confirming the launch of its two low-nicotine cigarettes as modified risk tobacco products, following the US Food and Drug Administration (FDA)’s marketing authorisation in December.
The New York-based company said a the pilot market launch of its VLN products, including a menthol cigarette, would begin in an unnamed “major metropolitan market”, with expansion to a full nationwide marketing and distribution launch soon after.
